Enacitib 50 mg contains Enasidenib, a targeted oral anticancer medicine used in the treatment of specific types of acute myeloid leukemia (AML). It is a selective inhibitor of mutant isocitrate dehydrogenase-2 (IDH2) and is designed for patients whose leukemia carries an IDH2 gene mutation. Enacitib offers a precision-based treatment approach, addressing the underlying genetic abnormality driving disease progression.

Enasidenib works by inhibiting the mutant IDH2 enzyme, which is responsible for producing an abnormal oncometabolite known as 2-hydroxyglutarate (2-HG). Elevated levels of 2-HG block normal blood cell differentiation and contribute to leukemic cell survival. By reducing 2-HG levels, Enacitib helps restore normal cellular differentiation, allowing immature leukemic cells to mature into functional blood cells rather than continuing uncontrolled proliferation.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Indications

Enacitib 50 mg is indicated for:

• Treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a confirmed IDH2 mutation.

• Use as directed by an oncologist based on molecular diagnostic testing.

Therapeutic Class

• Antineoplastic Agent

• IDH2 Inhibitor

Pharmacology

Enasidenib selectively targets mutant IDH2 enzymes without significantly affecting the normal (wild-type) IDH2. This selectivity helps reduce abnormal metabolite accumulation and promotes differentiation of leukemic blasts. Unlike traditional cytotoxic chemotherapy, Enacitib does not primarily kill cancer cells but instead induces their maturation, offering a different and often better-tolerated treatment strategy.

Following oral administration, Enasidenib is well absorbed and achieves steady plasma concentrations with continuous dosing. Clinical responses may take several weeks, reflecting its differentiation-based mechanism of action.

Dosage and Administration

• Enacitib is administered orally once daily, with or without food.

• Treatment is continued until disease progression or unacceptable toxicity.

• Dosage adjustments may be required based on tolerability, adverse effects, or clinical response.

• Regular monitoring of blood counts and biochemical parameters is essential during therapy.

Key Benefits

• Targeted therapy for IDH2-mutated AML.

• Oral, non-cytotoxic treatment option.

• Promotes leukemic cell differentiation rather than direct cell destruction.

• Suitable for patients who are not candidates for intensive chemotherapy.

Precautions and Warnings

• Differentiation syndrome is a known risk and requires prompt recognition and management.

• Regular monitoring of blood counts, liver function, and electrolytes is recommended.

• Use with caution in patients with hepatic impairment.

• Not recommended during pregnancy or breastfeeding.

  রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Adverse Effects

Common adverse effects may include nausea, diarrhea, fatigue, decreased appetite, elevated bilirubin levels, electrolyte imbalances, and leukocytosis. Most adverse reactions are manageable with supportive care, dose interruption, or adjustment under medical supervision.

Storage

Store below 30°C in a dry place, protected from light and moisture. Keep out of reach of children.

Enacitib 50 mg represents a significant advancement in the personalized treatment of AML, offering targeted efficacy, improved tolerability, and a valuable option for patients with IDH2-mutated disease.